Abstract
Substituted tryptamines with selective 5-HT(2)A/(2)C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.